CG Oncology Inc. Reports Q2 2026 Financial Results and Clinical Milestones

CG Oncology Inc. (NASDAQ: CGON) announced its second‑quarter 2026 financial results and key business updates on 6 August 2026. The company highlighted progress in its clinical program, regulatory strategy, manufacturing scale‑up, and commercial readiness, positioning it for long‑term success.

Financial Performance

  • Cash Position: CG Oncology reported approximately $1.0 billion in cash, cash equivalents, and marketable securities.
  • Run‑Rate: The liquidity level is projected to fund operations through 2029, giving the company a substantial runway to support its development and commercialization activities.
  • Stock Price: At the close on 4 August 2026, the share price was $72.42, within a 52‑week range of $23.65 – $77.

Clinical Program Highlights

  • PIVOT‑006: The phase‑III program evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate‑risk non‑muscle‑invasive bladder cancer (NMIBC) has accrued the majority of its target events. Topline data are anticipated in the near term.
  • BOND‑003 Cohort C: Results from the phase‑III BOND‑003 Cohort C study for high‑risk BCG‑unresponsive NMIBC were published in The Lancet Oncology. The publication reinforces the clinical evidence supporting cretostimogene.
  • Regulatory Outlook: CG Oncology expects to submit a Biologics License Application (BLA) for high‑risk BCG‑unresponsive NMIBC in the fourth quarter of 2026, following the positive outcomes from BOND‑003.

Commercial Readiness

CG Oncology continues to advance its manufacturing capabilities and prepare for potential market entry. The company’s strategy includes establishing commercial‑readiness initiatives to ensure rapid deployment should regulatory approval be obtained.

Market Context

CG Oncology operates in the health‑care sector and is headquartered in Irvine, United States. Its focus on bladder‑sparing therapeutics for bladder cancer positions it within a growing niche of oncology treatments aimed at improving patient quality of life while maintaining efficacy. The company’s market capitalization stands at $6.29 billion, underscoring investor confidence in its pipeline and strategic direction.

The company’s latest disclosures underscore its progress across clinical, regulatory, and commercial dimensions while maintaining a robust financial foundation to support continued development and eventual market entry.